Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 24:14:17562848211056157.
doi: 10.1177/17562848211056157. eCollection 2021.

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Carlos Taxonera  1 , María Pilar Martínez-Montiel  2 , Manuel Barreiro-de-Acosta  3 , Isabel Vera  4 , Rufo Lorente  5 , Pablo Vega  6 , María Teresa Diz-Lois  7 , Ana María Fuentes Coronel  8 , José Lázaro Pérez Calle  9 , Begoña Casis  2 , Rocío Ferreiro-Iglesias  3 , Marta Calvo  4 , David Olivares  10 , Cristina Alba  10
Affiliations

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Carlos Taxonera et al. Therap Adv Gastroenterol. .

Abstract

Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of inflammatory bowel disease (IBD) patients after switching their ADA regimen from 40 mg weekly to 80 mg EOW given with a single-dose pen.

Methods: In this multicentre cross-sectional study, patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW completed the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), a four-item questionnaire [a Likert-type 5-point scale for preferences, two closed questions for convenience and a 100-point visual analogue scale (VAS) to assess which escalated ADA regimen patients would prefer to continue] and two Health-Related Quality of Life (HRQoL) questionnaires: the generic European Quality of Life-5 Dimensions (EQ-5D) and disease-specific Spanish version of the Inflammatory Bowel Disease Questionnaire (SIBDQ-9).

Results: In total, 77 patients (64 Crohn's disease and 13 ulcerative colitis) were included. The TSQM score showed a notably high global satisfaction [83.4, standard deviation (SD) = 14.1] of patients with ADA 80 mg EOW given with a single-dose pen, with high TSQM scores for individual components: effectiveness (77.6, SD = 16.9), convenience (83.7, SD = 14.5) and side effects (86.1, SD = 23.4). Most of the patients (74%) preferred the ADA EOW regimen (59.7% had strong preference, 14.3% slight preference). ADA EOW interferes less with daily activity (59.7%) and with travel plans (81.8%). Most patients (77%) would prefer to continue with ADA EOW (mean VAS score of 84.7, SD = 24.1, where 100 indicates a preference for ADA EOW). Patients reported high HRQoL scores on both the EQ-5D (72.3, SD = 20.1) and SIBDQ-9 (75.1, SD = 14.7).

Conclusion: IBD patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW reported a higher preference for the EOW regimen and therefore most decided to continue with a single self-injection EOW.

Keywords: adalimumab; dose escalation; inflammatory bowel disease; patient-reported experience measures; single-dose pen.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. C.T. has served as a speaker, consultant and advisory board member for or has received research funding from MSD, AbbVie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Galapagos and Tillots. M.P.M.-M. has served as speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Pfizer, Kern Pharma, Takeda, Janssen, Shire Pharmaceuticals and Otsuka Pharmaceutical. M.B.-d.-A. has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gilead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma. I.V. has served as a speaker, consultant and advisory member for and has received funding from MSD, AbbVie, Pfizer, Ferring, Shire Pharmaceuticals, Takeda and Janssen. R.L. has served as a speaker, or has received research or education funding from MSD, AbbVie, Pfizer, Takeda, Janssen and Dr. Falk Pharma. P.V. has served as a speaker, consultant or advisory member for MSD, AbbVie, Ferring, Faes Farma, Takeda and Janssen. B.C. has served as a speaker, consultant and advisory board member for MSD, AbbVie, Ferring, Shire, Takeda and Janssen. R.F.-I. has served as a speaker, consultant and advisory board member for MSD, AbbVie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Adacyte and Tillots. J.L.P.C. has served as a speaker, consultant and advisory board member for MSD, AbbVie, Ferring, Faes Farma, Takeda and Janssen. C.A. has served as a speaker for Janssen and has prepared promotional material for Falk Pharma. These activities were not related to the present work. The remaining authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Self-administered questionnaire to evaluate preferences for adalimumab 40 mg weekly or 80 mg every other week: (a) a 5-point Likert-type scale for preferences, (b) two closed questions for convenience and (c) a 100-point visual analogue scale to evaluate the patient preference to continue with one or another adalimumab regimen.
See this image and copyright information in PMC

References

    1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52–65. - PubMed
    1. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257–265. - PubMed
    1. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141–151. - PubMed
    1. Wolf D, D’Haens G, Sandborn WJ, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 2014; 40: 486–497. - PubMed
    1. US Prescribing Information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf (accessed 12 June 2021).